Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 22,494 matching trials from the live ClinicalTrials.gov search.
Filters: Houston, Texas Clear all
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

NCT00003525
View directory record Official record
Conditions
Cervical Cancer Stage IV, Vulvar Cancer, Stage IV
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

NCT01694940
View directory record Official record
Conditions
Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
16
States / cities
San Diego, California • Stanford, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

A Study of PTC923 in Participants With Phenylketonuria

NCT05099640
View directory record Official record
Conditions
Phenylketonuria
Interventions
PTC923, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Stanford, California • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity

NCT01313299
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Nov 5, 2026, 4:23 AM EST
Recruiting Not applicable Interventional

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

NCT07214532
View directory record Official record
Conditions
Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Interventions
ctDNA-Guided Treatment Strategy
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
49
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

Study of Secukinumab With 2 mL Pre-filled Syringes

NCT02748863
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 1Phase 2 Interventional Results available

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00144963
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Vincristine Sulfate Liposomes Injection, Dexamethasone
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Phase 3 Interventional Results available

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

NCT03186898
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Interventions
Proton Therapy, Photon Therapy
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
27
States / cities
Atlanta, Georgia • Warrenville, Illinois • Baltimore, Maryland + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

NCT06611163
View directory record Official record
Conditions
Moderate to Severe Genital Psoriasis
Interventions
Tildrakizumab 100 mg, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Anaheim, California • Encinitas, California • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Phase 2 Interventional

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Active, not recruiting Phase 3 Interventional

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
45
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

NCT02627963
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Tivozanib hydrochloride, Sorafenib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 5, 2026, 4:23 AM EST
Completed Not applicable Interventional

Pilot Study Using a Dietary Intervention for Children With Irritable Bowel Syndrome

NCT01018498
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Restricted FODMAPs diet
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

NCT00448916
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Nov 5, 2026, 4:23 AM EST
Enrolling by invitation Phase 3 Interventional

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions
Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
1,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
81
States / cities
Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 4:23 AM EST
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

NCT00003487
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 2 Interventional Results available

Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease

NCT02435914
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
AGN-223575 ophthalmic solution, AGN-223575 vehicle ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
28
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 2 Interventional Results available

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

NCT02582684
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Dolutegravir, Lamivudine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

NCT03242252
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

NCT03502148
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma
Interventions
PRV111 (Cisplatin Transmucosal System)
Drug
Lead sponsor
Privo Technologies
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Louisville, Kentucky • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Nov 5, 2026, 4:23 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Clearance Of Mucus In Stents (COMIS)

NCT01370278
View directory record Official record
Conditions
Lung Neoplasms, Respiratory Failure, Pneumonia, Acute Coronary Syndromes, Unstable Angina, Myocardial Infarction, Cardiac Arrhythmia, Thromboembolic Disease
Interventions
Normal Saline, Sodium Bicarbonate
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

NCT00031915
View directory record Official record
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Park Ridge, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Nov 5, 2026, 4:23 AM EST
Completed Phase 2 Interventional Results available

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

NCT00404768
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
GSK221149A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
32
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Nov 5, 2026, 4:23 AM EST